Prasugrel-d4

• UNSPSC Description:

  Prasugrel-d4 is the deuterium labeled Prasugrel[1]. Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation[2].

• Target Antigen:

  P2Y Receptor

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  GPCR/G Protein

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Cardiovascular Disease

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(C1C([2H])([2H])C1([2H])[2H])C(C2=C(C=CC=C2)F)N3CC4=C(SC(OC(C)=O)=C4)CC3

• Molecular Weight:

  377.47

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.|[2]Wijeyeratne YD, et al. Anti-platelet therapy: ADP receptor antagonists. Br J Clin Pharmacol. 2011 Oct;72(4):647-57.|[3]Sugidachi A, et al. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite. J Thromb Haemost. 2007 Jul;5(7):1545-51.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  1189919-49-0